Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)
🏛 National Institutes of Health (HHS-NIH11)
✓ Free, no account · Source: Grants.gov · Last verified Jul 16, 2026
Can you apply?
This grant is for research organizations and academic institutions studying cancer therapy-induced adverse effects. Eligible applicants include 501(c)(3) nonprofits, universities, hospitals, and research institutions. Applicants must have the capacity to conduct clinical research and meet NIH compliance requirements.
The grant supports clinical research investigating cancer treatment side effects and developing interventions. It covers mechanism-based studies and clinical trials testing new approaches. Geographic scope is nationwide; international institutions may be eligible if they meet NIH requirements.
This R01 mechanism typically requires institutional research infrastructure and previous publication record in related areas. Most successful applicants have prior research funding and clinical research experience.
Not the right fit? Find grants for your organization in 5 questions →
Program description
The purpose of this Funding Opportunity Announcement (FOA) is to support collaborative research projects designed to address adverse sequelae of cancer therapies that persist and become chronic comorbidities or develop as delayed posttreatment effects. This FOA supports basic, translational, and clinical research projects that seek to identify the mechanisms of therapy-induced adverse sequelae, clinically characterize the adverse sequelae, or translate the mechanistic understanding into therapeutic approaches to prevent or minimize the development of long-term sequelae. Research projects should focus on mechanistic studies with translational endpoints and longitudinal clinical phenotyping to identify and validate clinical endpoints (biomarkers, imaging, patient-reported outcomes, or combined elements) for future use in clinical trials that will evaluate the efficacy of interventions designed to prevent or reduce specific adverse sequelae.
Who can apply
Eligible applicants
- 501(c)(3) Public Charity
- City / Municipal Government
- County Government
- Hospital
- Nonprofits
- Private University
- Public Authority
- Public K-12 School
- Public University
- Small Business (SBA-defined)
- Special District
- State Government
- Tribal Nation
- Tribal Organization
Demographic focus
How to apply
Application links
Required documents
- SF-424 (R&R) Federal form
- Project Narrative (specific aims, background, methods, timeline)
- Detailed Budget with justification
- Biosketches (senior/key personnel)
- Institutional support letter
- Preliminary data and figures
- Letters of collaboration (if multicenter)
- IRB approval or plan for human subjects research
- References
Program contact
- 👤 National Institutes of Health
- 📧 grantsinfo@nih.gov
- 📞 301-402-2541
Funding track record
Recent awards under CFDA 93.393 from the last 3 years — real organizations that won funding through this same program.
Top 10 Largest Recent Awards
-
$213,206,023
-
$56,551,552
-
$48,640,472
-
$47,009,863
-
$42,878,192
-
$37,448,862
-
$29,324,004
-
$26,395,336
-
$24,427,436
-
$23,149,727
Top States by Funding
- MA 10 awards $374.4M
- CA 10 awards $260.1M
- MN 4 awards $106.9M
- NY 7 awards $99.9M
- TN 7 awards $97.7M
Source: USAspending.gov — federal spending transparency. Data covers last 3 years.
Funding history
Annual funding for this program — Federal obligations (CFDA 93.393). How funding has trended year over year.
| 2024 | $754,945,159 | |
| 2025 | $834,514,512 | |
| 2026 est. | $520,096,276 |
FAQ
Can individual researchers apply?
No. Your institution must be the applicant and hold an active DUNS number and federal tax ID.
What research topics qualify?
Studies of side effects from cancer therapies and interventions to reduce or manage those sequelae.
Are clinical trials required?
No. The title says "optional." Both mechanism-based studies and trials are acceptable.
How long does the award last?
Typically 3-5 years. You can request multiple budget periods within the project period.
How competitive is this grant?
Very competitive. Expect strong preliminary data, published research, and detailed methodology.
💡 Tips for applicants
- Include strong preliminary data. Reviewers expect evidence your team can execute the proposed research.
- Focus on mechanism. Show you understand *why* adverse effects occur, not just documenting them.
- Detail clinical relevance. Explain how your findings will improve cancer survivor care and quality of life.
- Address feasibility clearly. Describe your patient recruitment plan, retention strategy, and institutional support.
- Align with NIH priorities. Reference recent NIH strategic plans on cancer survivorship and late effects.
⚠️ Common mistakes
Applicants submit weak preliminary data or lack published research in their specific topic area. Many fail to adequately justify clinical significance or explain how findings will change practice. Poor project scope—either too broad to complete in five years or too narrow to show impact.
Similar grants
- OPEN Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed) — National Institutes of Health
- OPEN Mechanisms that Impact Cancer Risk after Bariatric Surgery (R01 Clinical Trial Optional) — National Institutes of Health
- OPEN Early-Onset Cancers: Investigating Etiology, Mechanisms, and Early Detection Strategies (RP1 Clinical Trials Optional) — National Institutes of Health
- OPEN Mechanisms that Impact Cancer Risk after Bariatric Surgery (R21 Clinical Trial Not Allowed) — National Institutes of Health
- OPEN National Cancer Institute’s Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required) — National Institutes of Health